BREAKING
Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 2 hours ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 3 hours ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 6 hours ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 7 hours ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 9 hours ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 11 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 13 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 14 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 15 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 16 hours ago Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 2 hours ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 3 hours ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 6 hours ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 7 hours ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 9 hours ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 11 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 13 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 14 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 15 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 16 hours ago
ADVERTISEMENT
Market News

Boston Scientific (BSX) stock drops on weak Q4 preliminary revenue

Boston Scientific Corporation (NYSE: BSX) stock dropped over 6% on Tuesday after its preliminary fourth-quarter report. The shares have fallen over 5% in the past month and over 7% in the past five days despite rising over 20% in the past year. Investors remained concerned about the weakness that could lower the growth. For the […]

$BSX January 14, 2020 2 min read

Boston Scientific Corporation (NYSE: BSX) stock dropped over 6% on Tuesday after its preliminary fourth-quarter report. The shares have fallen over 5% in the past month and over 7% in the past five days despite rising over 20% in the past year. Investors remained concerned about the weakness that could lower the growth.

For the fourth quarter, Boston Scientific now expects revenue to grow about 13.4% to $2.9 billion and earnings to exceed its previous forecast range of $0.22-0.25 per share. Adjusted earnings are now anticipated to be within the previous range of $0.42-0.45 per share. Analysts had forecast EPS of $0.44 on revenue of $2.93 billion.

Boston Scientific Cardiovascular heart model
Image for representation. Courtesy: Jesse Orrico on Unsplash

For fiscal 2019, sales are projected to grow about 9.3% to $10.74 billion and earnings to exceed its previous estimates range of $0.72-0.75 per share. Adjusted earnings are predicted to be within the prior range of $1.55-1.58 per share. The consensus estimates EPS of $1.57 on revenue of $10.76 billion.

The preliminary bottom-line results were based on a significant non-cash tax benefit arising from an intra-entity asset transfer of intellectual property completed in the fourth quarter of 2019. The company has experienced more of a benefit accruing in the third quarter than the fourth quarter.

During the quarter, the company’s peripheral business is likely to slow due to tough comp from the Alluvia launch in the US a year ago and also a competitor to manufacturing issues. Also, a change of a distributor in Japan could slow the peripheral business.

ADVERTISEMENT

Read: SmileDirectClub stock rebounds amid growth concerns

The market experts believe that the company could be benefited from the continued solid momentum and likely to meet expectations for the fourth quarter. However, there could be a little bit of slowdown due to the recognition of sales upon cash collection, lumpier emerging markets, minor revenue recognition, and lesser benefits from the stocking.

On the operating margins standpoint, the company believes that its really diversified strength across the portfolio of all seven businesses as well as region-wise could show good performance during the quarter. The company is expected to release its final results and business highlights for the fourth quarter on February 5.

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

ADVERTISEMENT
ADVERTISEMENT